"I'll need to look at this but did we get any data suggesting any correlation between days post-event and MACE/HCHF in BOM1? Might extending the event days be a confounding variable?"

I didn't see that info for heart failure, but for 3-point MACE in BETonMACE the effect of apabetalone was more prominent in those >30 days post ACS event (11.9% vs. 9.6%, 0.79 hazard ratio) compared to those <30 days post ACS event (12.8% vs. 11.6%, 0.93 hazard ratio). 

"He said a couple of times that there were no other drugs that were in the running for therapeutics, or in phase 3 - but didn't we just see COLCORONA pass phase 3 a couple weeks ago?"

I was thinking the exact same thing when DM made that statement. Colchicine looked very promising in COLCORONA.

"I wonder why the focus on SGLT2i's and not DPP4i's. There were 298 patients on SGLT2i's with difference between groups of p=0.05, but everything was much better when looking at DPP4i's as well."

It could just be strategic. DPP4i's are kind of falling out of favor as go to choice for diabetes drug. DPP4i class has failed miserably at lowering MACE incidence in diabetics, whereas SGLT2i as a class have shown much cardio and renal promise. 

BDAZ